Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.

Novo Nordisk is a big time diabetes player, and while it is willing to dip its proverbial toes in the water on anti-obesity, Saxenda is not the drug that is front and center for the company.

Novo Nordisk showcased the efficacy of its obesity therapy, Saxenda (liraglutide), in children under 12 years of age with positive Phase III trial data.

Novo Nordisk A/S (NVO) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Novo Nordisk's (NOVOb.CO) new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity treatment ...